Interpace Diagnostics Group (NASDAQ:IDXG) Upgraded to “Hold” at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Interpace Diagnostics Group (NASDAQ:IDXG) from a sell rating to a hold rating in a research note issued to investors on Tuesday, ValuEngine reports.

Several other equities analysts also recently weighed in on the company. Maxim Group set a $2.00 target price on Interpace Diagnostics Group and gave the company a buy rating in a research report on Monday, October 21st. Oppenheimer assumed coverage on shares of Interpace Diagnostics Group in a research note on Thursday, September 26th. They set an outperform rating and a $3.00 price target on the stock. Finally, HC Wainwright reissued a buy rating and issued a $2.00 price objective on shares of Interpace Diagnostics Group in a research note on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $2.33.

Interpace Diagnostics Group stock opened at $0.45 on Tuesday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.57. Interpace Diagnostics Group has a fifty-two week low of $0.38 and a fifty-two week high of $1.15. The firm has a 50 day moving average price of $0.69 and a 200 day moving average price of $0.75.

Interpace Diagnostics Group (NASDAQ:IDXG) last posted its quarterly earnings data on Wednesday, November 13th. The business services provider reported ($0.19) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.19). Interpace Diagnostics Group had a negative return on equity of 58.48% and a negative net margin of 77.55%. The firm had revenue of $7.73 million for the quarter, compared to the consensus estimate of $10.00 million. As a group, equities research analysts anticipate that Interpace Diagnostics Group will post -0.44 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Perkins Capital Management Inc. increased its stake in shares of Interpace Diagnostics Group by 22.5% during the third quarter. Perkins Capital Management Inc. now owns 2,360,385 shares of the business services provider’s stock worth $1,876,000 after buying an additional 433,135 shares during the period. River & Mercantile Asset Management LLP acquired a new position in Interpace Diagnostics Group during the 2nd quarter worth approximately $468,000. Cambridge Investment Research Advisors Inc. increased its position in shares of Interpace Diagnostics Group by 98.0% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 44,750 shares of the business services provider’s stock valued at $32,000 after purchasing an additional 22,150 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in shares of Interpace Diagnostics Group by 22.3% in the 2nd quarter. Stonepine Capital Management LLC now owns 1,753,184 shares of the business services provider’s stock valued at $1,271,000 after purchasing an additional 319,154 shares in the last quarter. 18.74% of the stock is owned by institutional investors and hedge funds.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

Further Reading: Oversold

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.